Answers are grounded in this paper and cite their sources.
Introduction Inclisiran is a long-acting, injectable medication that significantly reduces low-density lipoprotein cholesterol (LDL-C) levels. VICTORION-SPIRIT (NCT04807400) was a type 1 hybrid effectiveness-implementation study conducted in primary care centres in England between July 2021 and January 2023. The process evaluation evaluated the implementation of inclisiran in a primary care setting. Methods The views of key stakeholders were sought via semi-structured interviews to gain insights on 'implementability' by exploring barriers and enablers to integrating inclisiran in primary care. Data were generated via interviews with 92 participants, including 56 patients, 28 providers and facilitators (general practice and trial management teams), and 8 Academic Health Science Network managers, and were analysed into themes that followed the Consolidated Framework for Implementation Research (CFIR). Results Implementation of inclisiran into the primary care setting in England was feasible and acceptable to providers and patients. Patients and general practitioners (GPs) saw the treatment as simple, efficacious and well tolerated. Patients were keen to receive the treatment and found the appointments accessible and straightforward. The local general practice was the preferred location for receiving injections as it was convenient and familiar. GPs saw inclisiran as a useful addition to lipid management. Beyond the trial, patients and health care providers thought the delivery of inclisiran could work well as a practice nurse-led service and be incorporated into existing patient review processes. Potential barriers to wider roll-out of inclisiran related to resource, prescriber confidence, and cost in primary care; the latter is a misconception as inclisiran is centrally funded. The point of care testing device used in the trial to measure lipid profiles was chosen to assess a potential reduction in health care resource burden and to understand whether immediate total cholesterol/LDL-C levels could improve patient activation, although it is not part of the current usual care processes and lost sensitivity at low LDL-C levels. Training and education were suggested to raise GP knowledge of and confidence in using inclisiran. Conclusions Patients and health care providers supported implementing inclisiran in the primary care setting across England. It was convenient for patients to receive inclisiran in general practice, and most providers felt the intervention was a valuable addition to existing lipid-lowering treatments. These findings indicate that treatment with inclisiran could feasibly be implemented as part of routine care, as has been demonstrated since the study concluded, through real-world use of inclisiran in primary care. Conflict of Interest Paul Wilson receives funding from the NIHR Applied Research Collaboration Greater Manchester. The NIHR Applied Research Collaboration Greater Manchester and The University of Manchester received funding from Novartis via NorthWest EHealth for the VICTORION-Spirit study.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: